CRVS - Corvus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Corvus Pharmaceuticals, Inc.

863 Mitten Road
Suite 102
Burlingame, CA 94010
United States

Full Time Employees49

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard A. MillerCo-Founder, Pres, CEO & Chairman305.96kN/A1951
Dr. Joseph J. BuggyCo-Founder & Exec. VP of Discovery Research143.57kN/A1967
Mr. Leiv LeaChief Financial Officer324.12kN/A1954
Dr. William Benton JonesSr. VP of Pharmaceutical Devel.N/AN/A1966
Mr. Daniel W. Hunt J.D.Sr. VP & Chief Bus. OfficerN/AN/A1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Corporate Governance

Corvus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.